|
1
|
Hickman JA: Apoptosis induced by
anticancer drugs. Cancer Metastasis Rev. 11:121–139. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Andersson A, Fagerberg J, Lewensohn R and
Ehrsson H: Pharmacokinetics of cisplatin and its monohydrated
complex in humans. J Pharm Sci. 85:824–827. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Szakacs G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wilson TR, Longley DB and Johnston PG:
Chemoresistance in solid tumours. Ann Oncol. 17:315–324. 2006.
View Article : Google Scholar
|
|
5
|
Sharom FJ: ABC multidrug transporters:
structure, function and role in chemoresistance. Pharmacogenomics.
9:105–127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Izumi H, Torigoe T, Ishiguchi H, Uramoto
H, Yoshida Y, Tanabe M, et al: Cellular pH regulators: potentially
promising molecular targets for cancer chemotherapy. Cancer Treat
Rev. 29:541–549. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Husain I, Mohler JL, Seigler HF and
Besterman JM: Elevation of topoisomerase I messenger RNA, protein,
and catalytic activity in human tumors: demonstration of tumor-type
specificity and implications for cancer chemotherapy. Cancer Res.
54:539–546. 1994.PubMed/NCBI
|
|
8
|
Liu H, Savaraj N, Priebe W and Lampidis
TJ: Hypoxia increases tumor cell sensitivity to glycolytic
inhibitors: a strategy for solid tumor therapy (Model C). Biochem
Pharmacol. 64:1745–1751. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boon T and Old LJ: Cancer Tumor antigens.
Current Opinion in Immunology. 9:681–683. 1997. View Article : Google Scholar
|
|
10
|
Singh Y, Palombo M and Sinko PJ: Recent
trends in targeted anticancer prodrug and conjugate design. Curr
Med Chem. 15:1802–1826. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koji K, Oumi N, Ryuichi M and Ryozo N:
Targeted anticancer immunotoxins and cytotoxic agents with direct
killing moieites. Sci World J. 6:781–790. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ohara H, Hasegawa Y, Kawabe T, Ichiyama S,
Hara T, Shimono Y, et al: Effect of gene transfer of tumor necrosis
factor receptors into human lung carcinoma cell line. Jpn J Cancer
Res. 89:589–595. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sakurai T, Amemiya A, Ishii M, Matsuzaki
I, Chemelli RM, Tanaka H, et al: Orexins and orexin receptors: a
family of hypothalamic neuropeptides and G protein-coupled
receptors that regulate feeding behavior. Cell. 92:573–585. 1998.
View Article : Google Scholar
|
|
14
|
Peyron C, Faraco J, Rogers W, Ripley B,
Overeem S, Charnay Y, et al: A mutation in a case of early onset
narcolepsy and a generalized absence of hypocretin peptides in
human narcoleptic brains. Nat Med. 9:991–997. 2000.PubMed/NCBI
|
|
15
|
Thannickal TC, Moore R, Nienhuis R,
Ramanathan L, Gulyani S, Aldrich M, et al: Reduced number of
hypocretin neurons in human narcolepsy. Neuron. 27:469–474. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nambu T, Sakurai T, Mizukami K, Hosoya Y,
Yanagisawa M and Goto K: Distribution of orexin neurons in the
adult rat brain. Brain Res. 827:243–260. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rouet-Benzineb P, Rouyer-Fessard C, Avondo
V, Pouzet C, Yanagisawa M, et al: Orexin acting at native OX1
receptor in colon cancer and neuroblastoma cells or at recombinant
OX1 receptor suppress cell growth by inducing apoptosis. J
Biological Chem. 279:45875–45886. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Spinazzi R, Rucinski M, Neri G,
Malendowicz LK and Nussdorfer GG: Preproorexin and orexin receptors
are expressed in cortisol-secreting adrenocortical adenomas, and
orexins stimulate in vitro cortisol secretion and growth of tumor
cells. J Clin Endocrinol Metab. 90:3544–3549. 2005. View Article : Google Scholar
|
|
19
|
Karteris E, Chen J and Randeva H:
Expression of human prepro-orexin and signaling characteristics of
orexin receptors in the male reproductive system. J Clin Endocrinol
Metab. 89:1957–1962. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Digby JE, Chen J, Tang JY, Lehnert H,
Matthews RN and Randeva HS: Orexin receptor expression in human
adipose tissue: effects of orexin-A and orexin-B. J Endocrinology.
191:129–136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reiter Y: Recombinant immunotoxins in
targeted cancer cell therapy. Adv Cancer Res. 81:93–124. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pastan I, Chaudhary V and FitzGerald DJ:
Recombinant toxins as novel therapeutic agents. Annu Rev Biochem.
61:331–354. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Johnson DA and Laguzza BC: Antitumor
xenograft activity with a conjugate of a Vinca derivative and the
squamous carcinoma-reactive monoclonal antibody PF1/D. Cancer Res.
47:3118–3122. 1987.PubMed/NCBI
|
|
24
|
Levin VA: Relationship of octanol/water
partition coefficient and molecular weight to rat brain capillary
permeability. J Med Chem. 23:682–684. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun H, Dai H, Shaik N and Elmquist WE:
Drug efflux transporters in the CNS. Adv Drug Delivery Rev.
55:83–105. 2003. View Article : Google Scholar
|
